Home › Compare › MIESF vs ABBV
MIESF yields 0.57% · ABBV yields 3.06%● Live data
📍 MIESF pulled ahead of the other in Year 7
Combined, MIESF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MIESF + ABBV for your $10,000?
Mitsui E&S Holdings Co., Ltd. engages in the shipbuilding and engineering businesses worldwide. The company operates through four segments: Ship, Ocean Development, Machinery, and Engineering. The Ship segment builds commercial ships, naval ships, high speed passenger/vehicle ferries, offshore structures, underwater TV vehicles, steel structures, and ship related equipment; and provides design engineering services. The Ocean Development segment provides floating production storage offloading vessels. The Machinery segment offers marine and stationary diesel engines, marine equipment, gas engines, steam turbines, blowers, process compressors and equipment, gas turbines, cogeneration systems, container cranes, industrial cranes, container terminal management systems, HWM manipulators, wave generators, and induction heaters, as well as equipment of radar sensing for underground and construction. The Engineering segment engages in the power generation and overseas civil/architectural works. The company also engages in the telecommunication equipment related, systems development, gas carriers engineering, and social infrastructure related businesses, as well as operates special facilities for naval ships and aircraft related business. The company was formerly known as Mitsui Engineering & Shipbuilding Co., Ltd. Mitsui E&S Holdings Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.
Full MIESF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.